- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01569061
Painless Laser Therapy for Overactive Bladder (PLTOAB)
A Double-blind, Randomized, Sham-controlled, Multicenter Clinical Trial to Assess the Effectiveness of Therapeutic Class IV Laser LCT-1000TM Treatment for Overactive Bladder Syndrome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a double-blind, randomized, sham-controlled, multicenter, clinical trial that will include enrollment of up to 200 subjects at up to 3 investigational sites.
The study population will be randomized at a 1:1 ratio into two groups: Sham Laser Group (SLG) and Active Laser Group (ALG). The Sham Laser Group will receive a sham LLLT procedure (no laser energy) and the Active Laser Group will receive an active LLLT procedure (laser energy).
Both groups will undergo 3 LLLT procedures per week for 3 weeks, for a total of 9 LLLT procedures. Whether the procedure will be a sham procedure (placebo) or an active LLLT application will be determined by randomization which will assign subjects to be treated with an LCT-1000TM labeled either Laser A or Laser B. The only difference between Laser A and Laser B is that one does not emit laser energy; therefore, both subjects and site research personnel will be blinded as to whether laser energy is actually applied to the subject.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ralph Zipper, MD
- Phone Number: 321-674-2114
- Email: drzipper@zipperurogyn.com
Study Contact Backup
- Name: James Raders, MD
- Phone Number: 321-674-2114
- Email: jraders@zipperurogyn.com
Study Locations
-
-
Florida
-
Melbourne, Florida, United States, 32901
- Recruiting
- Zipper Urogynecology Associates
-
Contact:
- Ralph Zipper, MD
- Phone Number: 321-674-2114
- Email: drzipper@zipperurogyn.com
-
Contact:
- James Raders, MD
- Phone Number: 321-674-2114
- Email: jraders@zipperurogyn.com
-
Principal Investigator:
- Ralph Zipper, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is female and at least 18 years of age at screening.
- A score of > 4 on the OAB-q short form for urgency.
- The subject has an average urinary frequency of > 10 voids per day.
- Self-reported bladder symptoms for > 3 months.
- Self-reported failed conservative care.
- The subject has discontinued all antimuscarinics for at least 2 weeks prior to screening.
- The subject is ambulatory and able to use the toilet independently and without difficulty.
- Negative pregnancy test in subjects of childbearing potential.
- Subject attests in writing that she has not had unprotected intercourse within 3 weeks prior to study enrollment and agrees to have no intercourse until treatments conclude.
- Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study.
- The subject (and caregiver, if applicable) is willing to participate in this study for at least 7 weeks.
- The subject is otherwise in general good health with no other major medical conditions.
Exclusion Criteria:
- The subject has vaginal bleeding.
- The subject has urinary or gastric retention or a neurogenic bladder.
- The subject is not capable of completing study questionnaires or undergoing portions of the study.
- The subject has been sexually assaulted.
- The subject has an alcohol or drug addiction.
- The subject has used isotretinoin (Accutane) within 6 months prior to study enrollment.
- The subject has cancer.
- The subject has used Botox® in the bladder or pelvic floor muscles within 12 months prior to study enrollment.
- The subject currently has a urinary tract infection or vaginal infection.
- The subject is using Interstim® or Bion®.
- Current use of TENS in pelvic region, back or legs.
- The subject is pregnant or lactating, or is of childbearing potential unless she is surgically sterile or she and/or her partner are using a medically acceptable method of birth control.
- Any use of light-activated drugs (photodynamic therapy) or heat sensitive medications within 30 days of first treatment.
- The subject has used an investigational drug/device therapy or participated in any clinical investigation involving or impacting gynecologic, urinary, or renal function within 4 weeks prior to study enrollment.
- The subject is otherwise determined, based on the opinion of the Investigator, to be an unsuitable candidate for enrollment in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Laser Group (ALG)
|
low level laser therapy (LLLT)
low level laser therapy (LLLT) sham treatment
|
Sham Comparator: Sham Laser Group (SLG)
|
low level laser therapy (LLLT)
low level laser therapy (LLLT) sham treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary efficacy endpoint will be the improvement of OAB symptoms and general quality of life due to the effect of LLLT treatment on OAB through week 7.
Time Frame: Visits 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 (over approximately 7 weeks)
|
Patients will undergo 3 LLLT procedures per week for 3 weeks, for a total of 9 LLLT procedures.
|
Visits 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 (over approximately 7 weeks)
|
The primary safety endpoint will evaluate the SLG and ALG treatment groups for differences in reported side effects and adeverse events throughout the trial, including LLLT treatment and follow-up.
Time Frame: Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 (over approximately 8 weeks)
|
Patients will undergo 3 LLLT procedures per week for 3 weeks, for a total of 9 LLLT procedures.
|
Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 (over approximately 8 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ralph Zipper, MD, Zipper Urogynecology Associates
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-179
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on LCT-1000TM (Manufacturer: LiteCure)
-
University of MiamiLiteCure LLCWithdrawn
-
Boston Children's HospitalUnited States Department of Defense; National Football LeagueCompleted